PACIFIC BIOSCIENCES OF CALIFORNIA, INC. Share Price & Technical Analysis
PACB · $2.37 (+29.51%)
Healthcare / Medical Devices
$2.37
+29.51%
Pacific Biosciences of California, Inc. designs, develops, and manufactures sequencing solutions to resolve genetically complex problems. The company provides sequencing systems; consumable products, including single molecule real-time (SMRT) technology; long-read sequencing; and various reagent kits designed for specific workflow, such as preparation kit to convert DNA into SMRTbell double-strand…
Price chart
Seasonality
Oct has 3 positive and 1 negative years (last 5 years shown)
62% return in 2026, -10% avg return in past 3 years.
Swipe sideways to see all months →
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Yr | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 26 | 15% | -23% | -19% | 14% | -6% | 13% | -18% | 0% | 85% | – | – | – | 62% |
| 25 | -21% | 0% | -20% | -8% | -9% | 20% | 17% | -7% | 0% | 77% | 0% | -14% | 34% |
| 24 | -33% | -17% | -31% | -58% | 6% | -26% | 50% | -33% | 21% | 29% | -14% | -5% | -110% |
| 23 | 34% | -19% | 27% | -9% | 17% | 8% | -1% | -14% | -27% | -24% | 35% | 17% | 45% |
| 22 | -45% | 5% | -23% | -32% | -11% | -23% | -2% | 37% | 2% | 42% | 24% | -23% | -49% |
Monthly return % by calendar month · historical pattern, not a forecast
Neutral · Emerging · Overbought
Pacific Biosciences of California, Inc. designs, develops, and manufactures sequencing solutions to resolve genetically complex problems. The company provides sequencing systems; consumable products, including single molecule real-time (SMRT) technology; long-read sequencing; and various reagent kits designed for specific workflow, such as preparation kit to convert DNA into SMRTbell double-stranded DNA library formats, including molecular biology reagents, such as ligase, buffers, and exonucleases. It also offers binding kits, such as modified DNA polymerase used to bind SMRTbell libraries to the polymerase in preparation for sequencing; and sequencing kits comprise reagents required for on-instrument, real-time sequencing, including the phospholinked nucleotides. In addition, the company provides Revio, Vega, and Sequel instruments which conduct, monitor, and analyze single-molecule biochemical reactions on SMRT cell microchips; short-read sequencing; and onso instrument. It serves academic and governmental research institutions, commercial testing and service laboratories, genome centers, public health labs, hospitals and clinical research institutes, contract research organizations, pharmaceutical companies, and agricultural companies. The company markets its products through a sales force and distribution partners in Australia, certain parts of Asia, Europe, the Middle East, Africa, Central America, and South America. It has a collaboration with DNAstack Inc. to provide federated dataset of HiFi whole genome sequencing data. The company was formerly known as Nanofluidics, Inc. and changed its name to Pacific Biosciences of California, Inc. in 2005. Pacific Biosciences of California, Inc. was incorporated in 2000 and is headquartered in Menlo Park, California.
Full AI Q&A, portfolio tracking, and live alerts in the app.
Key metrics
Market cap
$452.26M
P/E ratio
—
52W high
$2.73
52W low
$1.07
Volume
8,01,69,235
Beta
2.31
Related stocks in Healthcare
Eli Lilly And Company
₹1,165
Mckesson Corporation
₹886.5
Frequently asked questions
- What is PACIFIC BIOSCIENCES OF CALIFORNIA, INC. share price today?
- PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (PACB) last traded around $2.37 on StockPro. Prices refresh every few minutes during market hours.
- What technical signals does PACB have?
- StockPro currently tracks 2 active signal(s) for PACB, including breakouts, momentum, and volume patterns. See the signals panel on this page.
- How can I analyze PACIFIC BIOSCIENCES OF CALIFORNIA, INC. stock?
- Use the price chart, seasonality heatmap, key metrics, and AI insight on this page. For portfolio tracking and push alerts, download StockPro on Android or iOS.